After decades of research, a first-of-its kind vaccine designed to protect newborns against RSV, or respiratory syncytial virus, could be approved by August.
that the U.S. Food and Drug Administration has accepted its application for review and will make a decision on whether or not to approve the vaccine by August 2023.
“If approved, RSVpreF would help protect infants at their first breath from the devastating effects of this infectious disease, which though well-known, has been particularly evident throughout this RSV season,” Annaliesa Anderson, Ph.D., Pfizer's senior vice president and chief scientific officer of vaccine research and development,.
Pfizer's protein-based RSV vaccine works by vaccinating a pregnant person, who then passes on some protective antibodies to the infant.RSV usually causes mild, cold-like symptoms, but can become serious, especially for infants and older adults.
The virus is the most common cause of bronchiolitis and pneumonia in kids under the age of 1 in the U.S.,According to data collected from preliminary studies, Pfizer's vaccine was 82% effective at protecting newborns, within the first three months of life, from severe RSV illness. Within six months of an infants' life, the vaccine effectiveness dropped to 69%, according to Pfizer.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
1st RSV vaccine could be approved by August, pending FDA reviewThe FDA will decide whether or not to approve an RSV vaccine designed to protect newborns by August 2023.
Consulte Mais informação »
1st RSV vaccine could be approved by August, pending FDA reviewPfizer's vaccine would be the first RSV vaccine given to pregnant people to protect infants. The company said that there were 'no safety concerns' for vaccinated pregnant participants and their newborns during the trial.
Consulte Mais informação »
1st RSV vaccine could be approved by August, pending FDA reviewPfizer's vaccine would be the first RSV vaccine given to pregnant people to protect infants. The company said that there were 'no safety concerns' for vaccinated pregnant participants and their newborns during the trial.
Consulte Mais informação »
Pfizer RSV Vaccine That Protects Infants Could Receive FDA Approval This SummerThe single-dose RSV vaccine developed by Pfizer is administered to expectant mothers in the late second-to-third trimester of their pregnancy.
Consulte Mais informação »
Update: TWICE Leaves Fans “READY TO BE” Amazed In 1st Group Comeback TeasersUpdate: TWICE Leaves Fans “READY TO BE” Amazed In 1st Group Comeback Teasers
Consulte Mais informação »